Impact of race/ethnicity on survival among HIV-infected patients in care

Journal of Health Care for the Poor and Underserved

Volumn 20, Issue 4, 2009, Pages 982-995

  Lopez, Gregory ^a   Simone, Benedetto ^a   Madariaga, Miguel G ^a,b   Anderson, James ^a,c   Swindells, Susan ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b Section of Infectious Diseases   (United States)

^c Department of Family Studies and Human Development

Author keywords

AIDS; Ethnicity; HIV; Race; Survival

Indexed keywords

ADULT; AGE; ARTICLE; CD4 LYMPHOCYTE COUNT; ETHNOLOGY; FEMALE; HEALTH DISPARITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; UNITED STATES; VIRUS LOAD;

ADULT; AGE FACTORS; CD4 LYMPHOCYTE COUNT; FEMALE; HEALTH STATUS DISPARITIES; HIV INFECTIONS; HUMANS; MALE; MIDWESTERN UNITED STATES; MULTIVARIATE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; VIRAL LOAD;

EID: 74349103437     PISSN: 10492089     EISSN: None     Source Type: Journal    
DOI: 10.1353/hpu.0.0198     Document Type: Article

References (27)

1. Centers for Disease Control and Prevention. Epidemiology of HIV/AIDS-United States, 1981-2005. MMWR Morb Mortal Wkly Rep. 2006 Jun 2;55(21):589-92.
2. Lemp GF, Payne SF, Neal D, et al. Survival trends for patients with AIDS. JAMA. 1990 Jan 19;263(3):402-6.
3. Rothenberg R, Woelfel M, Stoneburner R, et al. Survival with the acquired immunodeficiency syndrome. Experience with 5833 cases in New York City. N Engl J Med. 1987 Nov 19;317(21):1297-302.
4. Curtis JR, Patrick DL. Race and survival time with AIDS: a synthesis of the literature. Am J Public Health. 1993 Oct;83(10):1425-8.
5. Swindells S, Cobos DG, Lee N, et al. Racial/ethnic differences in CD4 T cell count and viral load at presentation for medical care and in follow-up after HIV-1 infection. AIDS. 2002 Sep 6;16(13):1832-4.
6. Anastos K, Schneider MF, Gange SJ, et al. The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):537-44.
7. Silverberg MJ, Wegner SA, Milazzo MJ, et al. Effectiveness of highly-active antiretroviral therapy by race/ethnicity. AIDS. 2006 Jul 13;20(11):1531-8.
8. McGinnis KA, Fine MJ, Sharma RK, et al. Understanding racial disparities in HIV using data from the veterans aging cohort 3-site study and VA administrative data. Am J Public Health. 2003 Oct;93(10):1728-33.
9. Levine RS, Briggs NC, Kilbourne BS, et al. Black-White mortality from HIV in the United States before and after introduction of highly active antiretroviral therapy in 1996. Am J Public Health. 2007 Oct;97(10):1884-92.
10. Jain S, Schwarcz S, Katz M, et al. Elevated risk of death for African Americans with AIDS, San Francisco, 1996-2002. J Health Care Poor Underserved. 2006 Aug; 17(3):493-503.
11. Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA. 1999 Jun 23-30;281(24):2305-15.
12. McNaghten AD, Hanson DL, Dworkin MS, et al. Differences in prescription of antiretroviral therapy in a large cohort of HIV-infected patients. J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):499-505.
13. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC: U.S. Department of Health and Human Services, 2008. Available at: http://aidsinfo .nih.gov/contentfiles/AdultandAdolescentGL.pdf.
14. Shimizu SM, Chow DC, Katz AR, et al. Ethnic differences in HIV disease progression: a comparison of Asian/Pacific Islanders and Whites living in Hawaii. Ethn Dis. 2006 Winter;16(1):262-7.
15. Wohl D, McComsey G, Tebas P, et al. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis. 2006 Sep 1;43(5):645-53.
16. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998 Mar 26;338(13):853-60.
17. Blair JM, Fleming PL, Karon JM. Trends in AIDS incidence and survival among racial/ ethnic minority men who have sex with men, United States, 1990-1999. J Acquir Immune Defic Syndr. 2002 Nov 1;31(3):339-47.
18. Palella F, Baker R, Chmiel J, et al. Higher adjusted mortality rates among publicly insured patients and blacks in the HIV Outpatient Study. Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA: Feb 3-6, 2008; 530.
19. Kraut-Betcher J, Eisenberg M, Voytek C, et al. Examining racial disparities in HIV: lessons from sexually transmitted infections research. J Acquir Immune Defic Syndr. 2008 Mar 1;47 Suppl 1:S20-7.
20. Lemly D, Sheperd B, Hulgan T, et al. Race and sex differences in HAART use and mortality among HIV-infected people in care. Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA: Feb 3-6, 2008; 810.
21. Murrain M. Differential survival in blacks and Hispanics with AIDS. Ethn Health. 1996 Dec;1(4):373-82.
22. Cunningham WE, Hays RD, Duan N, et al. The effect of socioeconomic status on the survival of people receiving care for HIV infection in the United States. J Health Care Poor Underserved. 2005 Nov;16(4):655-76.
23. Cook JA, Burke-Miller JK, Cohen MH, et al. Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women. AIDS. 2008 Jul 11; 22(11):1355-63.
24. Ickovics JR, Meade CS. Adherence to antiretroviral therapy among patients with HIV: a critical link between behavioral and biomedical sciences. J Acquir Immune Defic Syndr. 2002 Dec 15;31 Suppl 3:S98-102.
25. King WD, Wong MD, Shapiro MF, et al. Does racial concordance between HIV-positive patients and their physicians affect the time to receipt of protease inhibitors? J Gen Intern Med. 2004 Nov;19(11):1146-53.
26. An P Martin MR Nelson GW, et al. Influence of CCR5 promoter haplotypes on AIDS progression in African-Americans. AIDS. 2000 Sep 29;14(14):2117-22.
27. Ribaudo HJ, Haas DW, Tierney C, et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis. 2006 Feb 1;42(3):401-7.